姓 名：徐聪聪
职称职务：青年特聘教授
电子邮箱：xucc@suda.edu.cn
联系电话：0512-65886182
个人简介：
徐聪聪，博士，苏州大学国际创新药学院青年特聘教授，上海市白玉兰计划浦江人才，江苏省青年科技托举人才。湖南大学化学学士，俄亥俄州立大学药学院获药剂科学博士（师从美国发明家院士郭培宣教授）。2020-2023 年于 mRNA 头部企业担任 mRNA 平台研发负责人，与美国百度研究院共同开发 mRNA 人工智能算法 LinearDesign（Nature, 2023）,并开发环状 RNA 人工智能算法 circDesign。推进多项mRNA疫苗和药物如个性化肿瘤疫苗（Science Advances, 2024 ）、新 冠 mRNA 疫 苗 产 品 进 入 海 外 临 床 研 究。2023 年受聘为苏州大学国际创新药学院青年特聘教授。主持或以子课题负责人承担国家自然科学基金委区域联合基金重点项目，国家自然科学基金民营企业创新发展联合基金项目，江苏省自然科学基础研究青年项目，国家卫生健康委党校慢病管理项目，上海市科技创新行动计划项目，苏州市医疗卫生创新科技计划项目，苏州大学高层次人才科研项目等。迄今为止以（共同）第一/通讯作者在 Nature, Nat. Biomed. Eng., Science Advances, Nano Today, J Control Release, Nano Research, Cancer Letters等期刊发表多篇论文。获得国际专利授权 5 项，提交 RNA 药物相关国内发明专利申请 6 项。
研究方向：
基于RNA平台技术的新型疫苗和创新药物的发现及工程化改造研究：
1) 新型RNA平台包括自复制型mRNA以及环状RNA的开发及设计
2) 针对神经退行性疾病、肿瘤及自免疾病mRNA药物的开发和机制探究
3) 人工智能算法指导的mRNA序列优化及设计
4) 核酸药物的递送系统开发和靶向机制研究
科研项目（在研）：
Ø 江苏省科技重大专项“创新生物药”项目，子课题负责人，2026-2029
Ø 江苏省自然科学基金青年项目，课题负责人，2025-2028
Ø 国家自然科学基金区域联合创新基金项目，主要参与人，2026-2029
Ø 国家自然科学基金民营企业创新发展联合基金项目，子课题负责人，2026-2029
Ø 江苏省科技重大专项“创新生物药”项目，主要参与人，2026-2029
Ø 苏州市科技攻关计划（医疗卫生创新）项目，主持，2025-2027
Ø 江苏省青年科技人才托举工程项目，主持，2025-2027
Ø 国家卫生健康委党校慢病管理项目，主持，2025-2027
Ø 横向课题，肾靶向递送小核酸技术开发，杭州鼎乐新为生物科技有限公司，主持，2025-2027
Ø 横向课题，体内CAR核酸药物递送技术开发，苏州贝伦生物科技有限公司，主持，2026-2027
Ø 横向课题，针对脑胶质瘤的靶向蛋白降解环状RNA药物开发，南京宁丹新药技术股份有限公司，主持，2026-2027
代表性论文：
1. Shi T, Li Y, Deng C, Ren Q, Xu C*, Zhong Z*. In vivo nano-engineering T cells for CAR-T therapy. J Control Release. 2025 Nov 1:114379. doi: 10.1016/j.jconrel.2025.114379. Epub ahead of print. PMID: 41183575
2. Ye, R., Ren, Q., Chang, L., Zhang, S., Deng, C., Cao, L., Shi, M., Lou, B., Meng, F., Du, S., Ren, K., Piao, X., Xu, C.*, Zhong, Z.* Administration route-commended concise organ-selective mRNA transfection (ACCOST) by cyclic disulfide-primed short polyethylenimine. Nano Today, 2025 Aug; (63)102741
3. Ren, Q., Zhao, X., Zhou, L., Meng, F., Deng, C., Meng, F., Zhou, F., Xu, C.*, Zhong, Z.* Monocyte-Driven Lymph Node Targeting of mRNA Cancer Vaccines via Transferrin Receptor Associating Polyplexes (TRAP). Nature Biomedical Engineering, 2026 In press
4. Binzel, D. #, Xu, C.# (co-first author), Binzel, K., Ghosh, A., Pippin, A., Li, X., Sechi, M., Knopp, M., Kumar, K., Guo, P.* RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis. RNA Nanomed, 2025 Aug 4; 2(1)
5. Xu, C. #, Chen, R., Pu,C., Wang, W., Tang, Y., Wang, Q., An, J., ... & Zhang, L.. (2025). circDesign Algorithm for Designing Synthetic Circular RNA. bioRxiv, 2025 April.
6. Fan T#, Xu C# (co-first author), Wu J#, Cai, Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci Adv. 2024 Oct 11;10(41):eadn9961. doi: 10.1126/sciadv.adn9961.
7. Cui G, Shao Y, Wang J, Xu C*, Jinping Zhang*, Zhiyuan Zhong*, Polymersome-mediated Cbl-b silencing activates T cells against solid tumors. Biomater. Sci., 2025, doi:10.1039/D5BM00001G
6. Ye, Z., Xu, C., Zhang, Y., Zhao, Y., Xu, C.* Targeted protein degraders based on biomacromolecules: current progress and challenges. Acta Pharmaceutica Sinica, 2025, 60(11): 3309-3317.
7. Xu C, Yin H, Yudhistira T, Li Z, Binzel D,*Guo P*, Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment. RNA NanoMed, 2024, (1) 109-123. doi:10.59566/ISRNN.2024.0101109.
8. Zhang, H.#, Zhang, L.#, Lin, A. #, Xu, C. # (co-first author), Li, Z., Liu, K., ... & Huang, L. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature, 2023, 1-3.
9. Yi Fang, Jing-Xin Li, Davone Duangdany, Yang Li, Xi-Lin Guo, Chanthala Phamisith, Ming-Yun Shen, Bo Yu, Bin Luo, Yu-Zhu Wang, Si-Jun Liu, Fan-Fan Zhao, Cong-Cong Xu, Xu-Hui Qiu, Rong-Juan Pei, Jie Wang, Haifa Shen, Wu-Xiang Guan, Hang-Wen Li, Mayfong Mayxay, Safety, immunogenicity and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: interim report of a Phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). EClinicalMedicine. 2023 Dec 13;67:102372. doi: 10.1016/j.eclinm.2023.102372.
10. Carcache PJ, Guo S, Li H, Zhang K, Xu C, Chiu W, Guo P. Regulation of reversible conformational change, size switching, and immunomodulation of RNA nanocubes. RNA. 2021 Sep 1;27(9):971-80.
11. Guo S., Xu C., Yin H., Hill J., Pi F., Guo P. (2019). Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation. WIREs Nanomedicine and Nanobiotechnology, 2019 Aug 27:e1582. doi: 10.1002/wnan.1582
12. Xu, C., Zhang, K., Yin, H., Li, Z., Krasnoslobodtsev, A., Zheng, Z., Ji, Z., Guo, S., Li, S., Chiu, W. and Guo, P., 2020. 3D RNA nanocage for encapsulation and shielding of hydrophobic biomolecules to improve the in vivo biodistribution. Nano Research, 13(12), pp.3241-3247.
13. Chen, Y., Li, J., Duangdany, D., Phamisith, C., Yu, B., Lan, S., Jin, L., Lv, D., Li, Y., Luo, B., Han, P., Wu, J., Wang, Y., Xu, C., Shen, M., Zhao, F., Liu, P., Pei, R., Shen, H., Guan, W., Li, H., Mayxay, M., Safety and Immunogenicity of SW-BIC-213, a Modified COVID-19 Lipo-Polyplex Mrna Vaccine, in Laotian Healthy Adults Aged 18 Years and Above: a Phase 1/2 Trial, Openalex, 2023
14. Xu C., Wang H., Yin H., Sechi M., Li Z., Kumar K., Tweedle M., Knopp M., Guo P. 2022. Small Molecule Conjugated RNA Nanoparticles for PET Imaging-guided Prostate Cancer Therapy, Under Submission.
15. Ghimire C, Wang H, Li H, Vieweger M, Xu C, Guo P. RNA nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity. ACS Nano. 2020 Sep 9;14(10):13180-91.
16. Li H., Wang S., Ji Z., Xu C., Shlyakhtenko L.S. and Guo P., Construction of RNA nanotubes. 2019. Nano Research, 12(8), pp.1952-1958.
17. Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release. 2019 Aug 22;. doi: 10.1016/j.jconrel.2019.08.021.
18. Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther. 2019 Jul 3;27(7):1252-1261. doi: 10.1016/j.ymthe.2019.04.018.
19. Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression. Redox Biol. 2019 Feb;21:101085. doi: 10.1016/j.redox.2018.101085.
20. Haque F†, Xu C†, Jasinski DL, Li H, Guo P. († Contributed equally) Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice. Methods Mol Biol. 2017;1632:359-380. doi: 10.1007/978-1-4939-7138-1_23.
21. Guo S, Xu C, Yin H, Guo P, Hill J, and Pi F. 2022. Tuning the Size, Shape, and Structure of RNA Nanoparticles for Favorable Cancer Targeting and Immunostimulation. RNA Nanotechnology and Therapeutics, pp.543-562.
22. Li W, Yang X, He L, Wang K, Wang Q, Huang J, Liu J, Wu B, Xu C. Self-Assembled DNA Nanocentipede as Multivalent Drug Carrier for Targeted Delivery. ACS Appl Mater Interfaces. 2016 Oct 5;8(39):25733-25740. doi: 10.1021/acsami.6b08210.
学生及博后指导成果：
07/2023常立民（2023级博士生），江苏省研究生科研创新计划，获批立项
11/2024史天宇（2024级博士生），江苏省研究生医药科研创新实践大赛，二等奖
11/2024史猛（博士后），第76批国家博士后面上项目，获批立项
03/2025张宇婷（2024级研究生），“挑战杯”课外学术科技作品竞赛，三等奖
07/2025李瑶（博士后），第77批国家博士后面上项目，获批立项
09/2025史猛（博士后），江苏省卓越博士后B档，获批资助
09/2025李瑶（博士后），江苏省卓越博士后B档，获批资助
09/2025史猛（博士后），国家资助博士后研究人员计划B档，获批资助
09/2025吴记传（博士后），江苏省卓越博士后C档，获批资助
09/2025李瑶（博士后），国家自然科学青年科学基金项目（C类），获批资助
11/2025忻铖杰（本科生），iCAN大学生创新创业大赛中荣获江浙赛区二等奖
11/2025任琼赭（博士生），江苏省研究生医药科研创新实践大赛，三等奖
11/2025徐聪聪，本科生“成长陪伴”卓越导师
招生需求：
课题组欢迎立志于科研且对RNA药物研发有浓厚兴趣的学生和博士后加入，参与RNA药物递送及药物设计方向的早期研究和转化应用，欢迎发送简历+姓名+申请位置至 xucc@suda.edu.cn